Paulina Niedziejko-Ćwiertnia

Design, Synthesis, and Antitumor Activity Evaluation of Novel Dual A2A/A2B Adenosine Receptor Antagonists.

The development of compound 45 is reported, a novel imidazopyrazine derivative acting as a long-lasting, dual A2A/A2B receptor antagonist with nanomolar in vitro potency, providing high oral bioavailability and systemic exposure across multiple preclinical species.